RE:Theralase = TLD-1433 Yeah Fred,
I'm still super excited about the super compounds and their potential, too early to know if any will be as practicable as 1433.
TLT stubbed their toe here with these first 12. Let's not forget though how complicated NMIBC DFOC is compared to other indications. Everyones bladders are different and the interior being so shiny and reflective has to be accounted for. This is a learning curve and they have only treated 18 humans so far. We will get fast track, at least, at some point. Due to Covid though, mostly, will take longer than before.
A partnership on Lung will be great, for now we should keep an eye on what happens at Roswell Park.
I think 2021 will be our year. 2020 is hindsight. ;-)
fredgoodwinson wrote:
TLD-1433 is the super compound. As Quattro mentioned it has built-in safety with its` steep green light gradient and high selectivity for surface cancers and when pre-incubated to create Rutherrin can treat deeper and larger tumours whether through multi-wavelength PDT or X-Ray.
Phase II NMIBC is doubly disappointing as if correctly dosed these first 12 could have showcased TLD-1433 to the wider world. It is galling to think that cruder photosensitisers have been activated with less attempted precision at doses sufficient to kill NMIBC while the much safer and more cytotoxic TLD-1433 has not.
The long-term intellectual property ownership of this and the suite of potential metal-based photosensitisers that the Company took under license from Sherri IS Theralase but TLD-1433 in particular as it has IND status and a growing Clinical database.
The great advances made and being made by Dr.Lilge in developing safe and effective treatment strategies should not restrict the Company from looking to commercialise TLD-1433 on as wide a basis as possible. Full Monte is open source and as Lumeda show the DFOC not the only device. It is time for deals to be done.